Form 4: Edwards Lifesciences CVP Sells Shares Under 10b5-1 Plan

Sentiment:

Insider Transaction Report 12 December 2025 5:57 PM

📋All filings for Edwards Lifesciences CORP

Edwards Lifesciences CVP Daniel J. Lippis sold 1,019 shares of common stock for $84.03 per share after exercising options, as part of a pre-arranged 10b5-1 trading plan.

Summary

Daniel J. Lippis, Corporate Vice President, JAPAC at Edwards Lifesciences Corp, reported transactions on December 12, 2025.
Exercised employee stock options to acquire 1,019 shares of common stock at an exercise price of $59.2567 per share.
Immediately sold 1,019 shares of common stock at a weighted average price of $84.0287 per share.
The sale price for the common stock ranged from $83.58 to $84.46.
These transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on July 30, 2025.
Following these transactions, Lippis beneficially owns 22,001.9103 shares of common stock directly.
Lippis also beneficially owns 5,095 employee stock options directly, which are exercisable as of May 8, 2020, and expire on May 7, 2026.

Sentiment

Score: 5

Explanation: A Form 4 filing for an insider sale under a 10b5-1 plan is generally neutral. It reflects a pre-planned transaction rather than a discretionary decision based on new information, thus not inherently positive or negative for the company's immediate outlook.

Future Outlook

Industry Context

Stakeholder Impact

Shareholders: Disclosure of insider trading activity provides transparency regarding executive compensation and stock ownership changes.

Key Dates

Date	Description
05/08/2020	Date employee stock options became exercisable.
07/30/2025	Date Rule 10b5-1 trading plan was adopted by the reporting person.
12/12/2025	Date of stock option exercise and subsequent sale of common stock.
05/07/2026	Expiration date of the employee stock options.

Recommendation

hold

The Form 4 details a pre-scheduled insider transaction under a Rule 10b5-1 plan, which is a routine disclosure and does not provide new fundamental information about the company's performance or future prospects. Therefore, it does not warrant a change from a 'hold' recommendation based solely on this filing.

Keywords

Edwards Lifesciences, EW, Insider Trading, Form 4, Stock Option Exercise, Stock Sale, 10b5-1 Plan, Daniel J. Lippis, Corporate Vice President

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.